price
GM
NYSE · GMAB
Genmab A/S
Healthcare · Biotechnology
$34.15
Up+$0.42 (+1.22%)
Updated Sep 16, 2026, 6:39 PM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 19.89B
- P/E ratio
- 14.56
- Dividend yield
- 0.00%
- 52-week range
- $23.62 – $35.43
- Volume
- 3.09M
- Avg. volume
- 2.09M
Price performance
GMAB price history
1M range · 20 trading sessions · Daily adjusted prices
GMAB closed at $34.15 after 20 trading sessions, up 3.61% for the selected period.
- Last close
- $34.15
- Period change
- +3.61%
- Period low
- $32.23
- Period high
- $34.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $32.34 | $34.185 | $32.34 | $34.15 | 3.09M |
| Sep 14, 2026 | $32.79 | $32.96 | $32.52 | $32.65 | 1.41M |
| Sep 11, 2026 | $32.45 | $32.70 | $32.27 | $32.47 | 1.39M |
| Sep 10, 2026 | $32.46 | $32.68 | $32.21 | $32.23 | 1.02M |
| Sep 9, 2026 | $33.47 | $33.75 | $32.98 | $33.04 | 2.13M |
| Sep 8, 2026 | $33.71 | $33.84 | $33.36 | $33.53 | 1.55M |
| Sep 4, 2026 | $33.96 | $34.19 | $33.545 | $33.60 | 1M |
| Sep 3, 2026 | $34.63 | $34.66 | $34.08 | $34.41 | 890.95K |
| Sep 2, 2026 | $34.04 | $34.50 | $33.74 | $34.215 | 2.08M |
| Sep 1, 2026 | $33.33 | $33.67 | $33.15 | $33.29 | 1.56M |
| Aug 31, 2026 | $32.76 | $33.26 | $32.5401 | $33.16 | 1.73M |
| Aug 28, 2026 | $33.78 | $33.9295 | $33.115 | $33.23 | 1.52M |
| Aug 27, 2026 | $33.91 | $34.165 | $33.67 | $34.10 | 1.87M |
| Aug 26, 2026 | $33.78 | $33.90 | $33.36 | $33.75 | 3.09M |
| Aug 25, 2026 | $33.81 | $34.4699 | $33.72 | $34.36 | 2.03M |
| Aug 24, 2026 | $32.82 | $33.32 | $32.74 | $33.02 | 3.25M |
| Aug 21, 2026 | $33.36 | $33.98 | $33.28 | $33.45 | 2.54M |
| Aug 20, 2026 | $33.60 | $33.77 | $33.20 | $33.41 | 6.35M |
| Aug 19, 2026 | $33.41 | $34.185 | $33.255 | $34.11 | 3.23M |
| Aug 18, 2026 | $32.86 | $33.11 | $32.66 | $32.96 | 2.71M |
Latest GMAB news
The latest Smart Investors Daily articles mentioning GMAB.
Stock researchResearch & News · SEC Filings
Loading stock research…

